In the context of tumor growth, which is often promoted by chronic inflammation, anti-PD-1/PD-L1 therapies selectively modulates inflammatory T-cell responses at the tumor site and inhibits PD-L1 induced tumor function. Here, CD274 is linked to neoplasm.